Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BNPP Exane upgrades Currys, says iD Mobile is underappreciated

(Sharecast News) - BNP Paribas Exane upgraded Currys on Thursday to 'outperform' from 'neutral' and lifted the target price to 135p from 115p as it said the iD Mobile business is an underappreciated driver of the company's growth, "enhancing sales, margins, and underpinning valuation". It noted that iD Mobile is worth nearly one-third of Currys' market capitalisation. "Its leading price proposition can continue to attract subscribers, driving sales and expanding gross margins," it said.

Other drivers include a tech replacement cycle, new product categories, margin-accretive services, and B2B investments, BNP said.

"With a stronger balance sheet, share buybacks are on the horizon."

BNP said gross margin expansion should come from the sale of mobile services in the UK & Ireland and a focus on profitable sales and services in the Nordics.

The bank said it expects this to enable Currys to achieve its target of "at least" 3% adjusted EBIT margins by FY Apr-29E.

At 1300 BST, the shares were up 0.5% at 112.30p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.